Modulation of doxorubicin-induced expression of the multidrug resistance gene in breast cancer cells by diltiazem and protection against cardiotoxicity in experimental animals

Hamdan S. Al-malky1, Abdel-Moneim M. Osman1,2, Zoheir A. Damanhouri1, Huda M. Alkreathy1, Jumana Y. Al Aama3,4, Wafaa S. Ramadan5,6, Ali A. Al Qahtani1 and Hadiah B. Al Mahdi3,4

Abstract

Background: Doxorubicin (DOX) is one of the most important anticancer agents used in treating breast cancer. However, chronic cardiotoxicity and multidrug resistance limit the chemotherapeutic use of DOX.

Methods: This study aimed to evaluate the capability of calcium channel blocker diltiazem (DIL) to reverse DOX resistance in breast cancer MCF-7 cells and to confer protection against DOX-induced cardiotoxicity in Wistar rats. For this purpose, we explored the effects of DOX on cell cycle phase distribution and expression of ABCB1, FOXO3a, and p53 genes in the presence and absence of DIL (20 μg/ml) and studied the ability of DIL to prevent DOX-induced cardiotoxicity after a single injection of DOX (15 mg/kg) in male Wister rats.

Results: We found that compared with DOX alone treatment, DIL + DOX treatment down regulated the ABCB1 gene expression by > fourfold but up regulated the FOXO3a and p53 genes expression by 1.5 fold. DIL treatment conferred protection against DOX-induced cardiotoxicity, as indicated by a decrease in the levels of the cardiac enzyme creatine kinase MB and malondialdehyde and an increase in the total antioxidant capacity and glutathione peroxidase levels. These biochemical results were further confirmed by the histopathological investigation of cardiac cells, which showed normal cardiac cells with central vesicular nuclei and prevention of DOX-induced disruption of normal cardiac architecture in the DIL to DOX group.

Conclusions: Taken together, our results indicate that DIL treatment can reverse the resistance of breast cancer cells to the therapeutic effects of DOX and can protect against DOX-induced cardiotoxicity in rats.

Keywords: Doxorubicin, Diltiazem, MCF-7 cells, MDR, Cardiotoxicity
Background

Multidrug resistance (MDR) continues to be a major clinical obstacle to the effects of cancer chemotherapy. MDR cancer cells are resistant to the naturally occurring cancer drugs, such as epipodophyllotoxins, vinca alkaloids, and anthracyclines, but are not cross-resistant to antimetabolites, alkylating agents, and cisplatin [1]. Doxorubicin (DOX) is a cytotoxic anthracycline antibiotic used for treating various types of cancers, such as Hodgkin and non-Hodgkin’s lymphoma, multiple myeloma, sarcoma, pediatric cancers, and breast, lung, ovarian, and thyroid cancers [2]. Several studies have confirmed the superiority of the regimens containing anthracyclines over those lacking them [3, 4]. As with other anticancer agents, the clinical use of DOX is hindered by tumor resistance and toxicity to healthy tissues [5]. Resistance to this drug is common, thus representing the main obstacle to the effective treatment of the disease [6, 7]. To counter MDR to the effects of breast cancer therapeutics, a wide range of compounds capable of inhibiting the MDR gene have been studied. Such inhibitors include, but are not limited to, the anti-HIV protease inhibitors ritonavir and nelfinavir, fumitremorgin C, and biochanin A. The major side effect of DOX is cardiotoxicity; therefore, strategies that minimize this side effect are urgently needed. Diltiazem (DIL) is a calcium channel blocker (CCB) that is widely used in the treatment of various indications. Cornwell et al. [8] reported that DIL, along with other CCBs, reverses MDR by binding to membrane vesicles and proteins associated with MDR development in tissue culture cells. Therefore, our study focused on investigating the molecular mechanisms underlying DIL-induced enhancement in the cytotoxic activity of DOX by measuring the expression of genes responsible for drug resistance, apoptosis induction, and cell cycle disturbance. Moreover, we evaluated the protective effect of DIL against DOX-induced cardiotoxicity in Wistar rats by evaluating total antioxidant capacity (TAC) and the levels of creatine kinase-MB (CK-MB), glutathione peroxidase (GPx), and malondialdehyde (MDA) and by performing histopathological investigation of cardiac tissue.

Materials and methods

Drugs and chemicals

DOX, DIL and Trypan blue powder were purchased from Sigma Aldrich Co. (Saint Louis, Missouri, USA) while Verapamil was purchased from Abbott. Fetal bovine serum (FBS), Dulbecco’s Modified Eagle Medium (DMEM), Trypsin–EDTA (0.05%) and phosphate buffered saline (PBS, pH 7.4) were purchased from Thermo Fisher Scientific Inc (USA). Acridine orange (AO) (Molecular Probes, Eugene, OR, cat. no. A1301) and Giemsa stain (GS-10), rhodamine 123 (R8004 SIGMA) have been also supplied. The cell cycle determination kit was purchased from Cayman Chemical Company (USA). Animal kits include Rat CK-MB (Catalog No: E-EL-R1327 (USA)), MDA (Catalog No: E-EL-0060 (USA)), TAC (Catalogue No: 201-11-1187 (USA)) and GPx (Catalog No: CAT. No. GP 2524 (Biodiagnostic, Dokki, Egypt).

Cells and cell cultures

For use in this study, human breast cancer cell line MCF-7 was obtained from the National Cancer Institute, Cairo University, Egypt. The adherent cells were grown as a monolayer in DMEM supplemented with penicillin (100 IU/ml), streptomycin (100 µg/ml), and 10% FBS. Cells were cultured at 37 °C in a humidified 5% CO₂ atmosphere and were passaged every 4–5 days.

Cell cycle analysis

Cells were seeded in six-well plates at a density of 10^5–10^6 cells/well in DMEM supplemented medium and incubated in a CO₂ incubator at 37 °C for at least 24 h. DOX at 0.25 or 1 µg/ml concentration and/or DIL at 20 µg/ml concentration were then added, followed by incubation for additional 48 h. Subsequently, the cell medium was removed, and the cells were washed with PBS and harvested with trypsin/ethylenediaminetetraacetic acid (EDTA). Following trypsinization, cells were washed twice with an assay buffer. The cell pellet was re-suspended in the assay buffer to a density of 1 × 10^6 cells/ml. Subsequently, 1 ml of a fixative agent was added to each sample to fix and permeabilize the cells for at least 2 h prior to propidium iodide (PI) staining. Fixed cells were centrifuged at 500×g for 5 min, and the fixative agent was decanted thoroughly. The cell pellet was then suspended in the PI staining solution and incubated for 30 min at RT in the dark. Cell cycle analysis was performed using BD FACS Aria III flow cytometer (BD, San Jose, CA, USA) as per the method described by Sulic et al. [9].

RNA isolation, cDNA synthesis, and reverse transcription quantitative PCR (RT-qPCR)

TaqMan gene expression assay was performed for ABCB1, FOXO3a, and p53 genes using a standard real-time PCR (Applied Biosystems, Foster City, CA, USA). The amplification was performed using TaqMan probe, RNA isolation, cDNA synthesis, and RT-qPCR.

Cells were seeded in six-well plates at a density of 10^5–10^6 cells/well in DMEM supplemented medium and were cultured in a CO₂ incubator at 37 °C for at least 24 h. Cells were then incubated with DOX at 0.25 or 1 µg/ml concentration and/or DIL at 20 µg/ml concentration for additional 48 h. Subsequently, the cell medium was removed, and the cells were washed with PBS. Total RNA was isolated from cultured cells using the QIAamp RNA
mini kit (Catalog no. 52304; Qiagen, Germany) according to the manufacturer's instructions. RNA samples (1 μg) were reverse transcribed to cDNA using the High-Capacity RNA-to-cDNA Kit (Catalog no. 4387406; Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. RT-qPCR was performed on an Applied Biosystems 7500 Fast Real-Time PCR System using TaqMan® Gene Expression assay. TaqMan probes for ABCB1 gene (Assay ID: Hs00184500_m1), FOXO3a gene (Assay ID: Hs00818121_m1), TP53 gene (Assay ID: Hs00818121_m1), and the housekeeping gene RNA18S5 (Assay ID: Hs03928990_m) were obtained from Applied Biosystems. Data were analyzed, and amplification plots were generated using the 7500 Fast Real-Time PCR software. The comparative CT method \(2^{-\Delta\Delta CT}\) was used for relative quantification of the target gene as follows: 
\[ \Delta\Delta CT = (CT_{\text{target gene}} - CT_{\text{RNA18S5}}) - (CT_{\text{control sample}} - CT_{\text{RNA18S5}}) \]
where \(\Delta\Delta CT\) is the expression change of the target gene normalized to RNA18S5 relative to the copy number of the target gene in control.

Gene expression data analysis
Data were analyzed, and amplification plots were generated using the 7500 Fast Real-Time PCR software. The comparative CT method \(2^{-\Delta\Delta CT}\) was used for relative quantification of the target gene as follows: 
\[ \Delta\Delta CT = (CT_{\text{target gene}} - CT_{\text{RNA18S5}}) - (CT_{\text{treated sample}} - CT_{\text{RNA18S5}}) = (CT_{\text{treated sample}} - CT_{\text{control sample}}) - (CT_{\text{treated sample}} - CT_{\text{RNA18S5}}) \]

Evaluation of DOX-induced cardiotoxicity in the presence of DIL
Fifty-six male Wistar rats were divided into four equal groups of 14 animals. Group I received normal saline i.p. (0.5 ml/200 gm) and was reserved as the control group. Group II received DIL (4 mg/kg body weight, i.p.). Group III received DOX (15 mg/kg body weight, i.p.). Group IV received both DIL (4 mg/kg body weight, i.p.) and DOX (15 mg/kg body weight, i.p.) simultaneously. At the end of the experiment period (48 or 72 h), rats were anesthetized to collect blood samples from the orbital rim; the blood samples were rapidly centrifuged for serum separation and were stored at –80 °C until further use for evaluating cardiac CK-MB level, MDA level, TAC, and GPx level using commercial kits.

Histopathological examination
The rats were sacrificed by decapitation, and their hearts were extracted immediately by opening their chest. Heart samples were immediately washed with saline, and part of the left ventricle was fixed in 10% phosphate-buffered formalin for 48 h and prepared for light microscopy.

Statistical analysis
Statistical analysis was performed using SPSS version 21. One-way analysis of variance followed by least significant difference for post hoc analysis and was performed for multiple comparisons. Statistical significance was considered at P values of ≤ 0.05.

Results

Effect of DOX and/or DIL treatment on cell cycle phase distribution of MCF-7 cells
Figure 1 shows the effect of 0.25 and 1 μg/ml DOX and/or 20 μg/ml DIL on cell cycle phase distribution assessed using flow cytometry after staining the cells with PI. We found that 0.25 and 1 μg/ml DOX treatment resulted in 34.1% and 37.5% accumulation of cell population in the G2/M phase, respectively, compared with the control. This cell accumulation in the G2/M phase significantly increased after the addition of 20 μg/ml DIL to DOX treatment (both concentrations).

Evaluation of ABCB1 gene expression in MCF-7 cells by RT-qPCR
Figure 2 shows the relative expression of ABCB1 mRNA by RT-qPCR. ABCB1 was over expressed in MCF-7 cells after treatment with 0.25 and 1 μg/ml DOX. This over expression of ABCB1 mRNA decreased by 2.3 and 4.5 fold, respectively, after the addition of 20 μg/ml DIL, indicating that the addition of DIL reversed ABCB1/P-gp-mediated MDR.

Evaluation of FOXO3 gene expression in MCF-7 cells
Figure 3 shows the relative expression of FOXO3a mRNA by RT-qPCR. The relative expression of FOXO3a in MCF-7 cells was 0.39 and 0.45 after treatment with 0.25 and 1 μg/ml DOX, respectively. This expression increased by 1.7 and 1.3 fold to 0.65 and 0.58, respectively, after the addition of 20 μg/ml DIL.

Evaluation of p53 gene expression in MCF-7 cells
Table 1 shows the relative expression of p53 by RT-qPCR. P53 was over expressed in MCF-7 cells after treatment.
with 0.25 and 1 μg/ml DOX. This expression increased by 1.4 and 1.5 fold, respectively, after the addition of 20 μg/ml DIL.

**Evaluation of CK-MB levels**

Table 2 shows the effect of DOX and/or DIL treatment on serum CK-MB levels in rats. After 48 and 72 h of DOX treatment, the CK-MB levels were significantly increased.
Fig. 2 Evaluation of ABCB1 gene expression in MCF-7 cells by RT-qPCR. The delta–delta CT method was used to determine the fold change for ABCB1 gene relative expression in MCF-7 cells that were treated with DOX and/or DIL for 48 h. The values represent the mean ± SD (n = 2). *Significantly different from corresponding DOX at p-value < 0.05.

Fig. 3 Evaluation of FOXO3a gene relative expression in MCF-7 cells by RT-qPCR. The delta–delta CT method was used to determine the fold change for FOXO3a gene expression in MCF-7 cells that were treated with DOX and/or DIL for 48 h. The values represent the mean ± SD (n = 2). *Significantly different from corresponding DOX at p-value < 0.05.
in rats by 6.7 and 5.8 fold, respectively, compared with the control. These CK-MB levels decreased significantly by 1.8 and twofold, respectively, after the addition of DIL.

Evaluation of MDA levels
Table 3 shows the effect of DOX and/or DIL treatment on the MDA levels in rats. After 48 and 72 h of DOX treatment, the MDA levels were significantly increased in rats by 2.5 and threefold, respectively, compared with the control. The addition of DIL to DOX treatment restored the MDA levels to nearly the normal level.

Evaluation of total antioxidant capacity
Table 4 shows the effect of DOX and/or DIL treatment on TAC levels in rats. After 48 and 72 h of DOX treatment, the TAC levels were significantly decreased in rats by 52% and 43%, respectively, compared with the control. The addition of DIL to DOX treatment restored the TAC levels to nearly the normal level.

Evaluation of serum GPx levels
Table 5 shows the effect of DOX (15 mg/kg, i.p.) and/or DIL (4 mg/kg, i.p.) on serum GPx levels in rats. After 48 and 72 h of DOX treatment, the GPx levels significantly decreased in rats by 1.8 and twofold, respectively, compared with the control. The addition of DIL to DOX treatment restored the GPx levels to the normal level.

Histopathological investigation of heart tissue after DOX and/or DIL treatment
DIL treatment alone (Fig. 4b) showed well-formed architecture of cardiac muscle fibers picture like control

### Table 1 Evaluation of p53 gene expression in MCF-7 cells

| Treatment                         | Relative expression of p53 |
|-----------------------------------|--------------------------|
| DIL 20 µg/ml                      | 1.06 ± 0.65              |
| DOX 0.25 µg/ml                    | 1.20 ± 0.64              |
| DOX 0.25 µg/ml + DIL 20 µg/ml     | 1.71 ± 1.4               |
| DOX 1 µg/ml                       | 1.43 ± 1.5               |
| DOX 1 µg/ml + DIL 20 µg/ml        | 2.21 ± 1.1              |

Relative p53 mRNA gene expression level by RT-qPCR in MCF-7 cells that were treated with DOX and/or DIL for 48 h. The values represent the mean ± SD

* Significantly different from corresponding DOX at p-value < 0.05 (the delta–delta CT method)

### Table 2 Effect of DOX and/or DIL on serum CK-MB level

| Treatment                         | CK-MB (pg/ml) |
|-----------------------------------|---------------|
|                                   | (48 h)        | (72 h) |
| Control                           | 103 ± 14      | 112 ± 11 |
| DIL (4 mg/kg, i.p.)               | 100 ± 10      | 104 ± 21 |
| DOX (15 mg/kg, i.p.)              | 690 ± 38a     | 659 ± 48a |
| DOX + DIL (administered simultaneously) | 367 ± 87b | 348 ± 19b |

Data are expressed as mean ± SD of experiment in male Wistar rats after 48 h and 72 h (n = 2)

* Significantly different from control at p-value < 0.05

### Table 3 Effect of DOX and/or DIL on MDA level

| Treatment                         | MDA (ng/ml) |
|-----------------------------------|-------------|
|                                   | (48 h)      | (72 h) |
| Control                           | 53 ± 17     | 52 ± 4  |
| DIL (4 mg/kg, i.p.)               | 74 ± 16     | 73 ± 6  |
| DOX (15 mg/kg, i.p.)              | 138 ± 21a   | 152 ± 31a |
| DOX + DIL (administered simultaneously) | 76 ± 42b | 99 ± 2a |

Data are expressed as mean ± SD of experiment in male Wistar rats after 48 h and 72 h (n = 2)

* Significantly different from control at p-value < 0.05

### Table 4 Effect of DOX and/or DIL on serum TAC

| Treatment                         | Total antioxidant capacity (U/ml) |
|-----------------------------------|----------------------------------|
|                                   | (48 h)                           | (72 h) |
| Control                           | 27 ± 12                          | 28 ± 3  |
| DIL (4 mg/kg, i.p.)               | 28 ± 3                           | 30 ± 5  |
| DOX (15 mg/kg, i.p.)              | 13 ± 7a                          | 16 ± 2a |
| DOX + DIL (administered simultaneously) | 31 ± 5b | 30 ± 1b |

Data are expressed as mean ± SD of 2 experiments in male Wistar rats after 48 h and 72 h

* Significantly different from control at p-value < 0.05

### Table 5 Effect of DOX and/or DIL on serum GPx level

| Treatment                         | Glutathione peroxidase (U/ml) |
|-----------------------------------|------------------------------|
|                                   | (48 h)                       | (72 h) |
| Control                           | 9.6 ± 0.48                   | 9.7 ± 0.72 |
| DIL (4 mg/kg, i.p.)               | 9.8 ± 0.72                   | 10.1 ± 0.46 |
| DOX (15 mg/kg, i.p.)              | 5.4 ± 0.33a                  | 4.8 ± 0.91a |
| DOX + DIL (administered simultaneously) | 9.4 ± 0.86b | 9.5 ± 0.42b |

Data are expressed as mean ± SD of 2 experiments in male Wistar rats after 48 h and 72 h

* Significantly different from corresponding control at p-value < 0.05

* Significantly different from corresponding DOX at p-value < 0.05
(Fig. 4a). Light photomicrographs (Fig. 4c) showed the effect of DOX (15 mg/kg) treatment on the myocardium tissue of rats. DOX treatment showed a marked disruption of normal cardiac architecture, congestion of blood vessels and capillaries, condensed pyknotic peripheral nuclei and multiple areas of fragmented cardiac muscle fibers. The histopathological changes induced by DOX were less when combined with DIL therapy. The combination of DOX (15 mg/kg) and DIL (4 mg/kg) (Fig. 4d) showed normal branching cardiac muscle fibers with central vesicular nuclei with normal cardiomyocytes.

Discussion
DOX is an anthracycline antibiotic with a wide spectrum of antitumor activity. It is commonly used in treating different cancers. Unfortunately, in addition to chemoresistance that may affect DOX against tumors. In the other part using DOX may cause chronic cardiotoxicity and cardiomyopathy development which is the main factor that limits the chemotherapeutic uses of DOX [10]. Resistance to chemotherapeutic drugs is one of the important reasons for cancer recurrence, progression, and metastasis. Our study focused on investigating whether DIL can overcome the resistance to DOX therapy and enhance the cytotoxic effects of DOX against the growth of MCF-7 human breast cancer cell line. In this case, we studied the possible modulatory mechanisms changes in cell cycle phase distribution, the molecular mechanism of inhibition of ABCB1 gene expression responsible for drug transport as well as expression of the tumor suppressor genes FOXO3a and p53. In the second part of this study, we also investigated the possible protection conferred by DIL against DOX-induced cardiotoxicity in Wistar rats through many indicators that targeted the oxidative stress.

It is well known that DNA damage caused by different cytotoxic agents, induced cell cycle arrest at G1, S, G2, thereby preventing replication of damaged DNA.
or aberrant mitosis which if not repaired, may result in either tumorigenesis or apoptosis [11]. It has been justified based on the fact that anthracyclines are mostly active on proliferating cells in G2/M phase due to the maximal expression of their target enzyme TOPO II at these phases [12, 13].

In our study, the results showed that DIL treatment induced accumulation of G2/M phase by approximately threefold when added to both DOX concentrations compared to control and by 1.4 fold compared to the corresponding DOX-treated cells administered alone. In general, CCBs have been demonstrated to induce apoptosis, decrease cellular proliferation indices, and decrease metastatic potential and invasion in many cancer cell lines [14, 15]. In the majority of these studies, the authors were unable to demonstrate that this effect resulted due to inhibiting the calcium-dependent secondary messenger systems within these cells.

The other problem that affects the cytotoxicity effect of DOX is MDR development and subsequent relapse on chemotherapy, but unfortunately, the underlying molecular processes remain poorly understood [16]. In general, ATP-binding cassette (ABC) transporters play important roles in MDR in breast cancer; an increase in ABC expression results in a reduced response to a range of chemotherapeutic drugs and the eventual reduction in survival among breast cancer patients [17].

We showed that ABCB1 mRNA was over expressed in MCF-7 cells after DOX treatment, possibly leading to the drug resistance (Fig. 2). On the other hand, DIL treatment was found to reverse ABCB1/P-gp mediated MDR, as shown by > fourfold decrease in ABCB1 mRNA expression after the addition of DIL. In fact, this down-regulation re-sensitized MCF-7 cells to DOX treatment and confirmed that ABCB1 protein expression was knocked down by DIL treatment, leading to possible increased DOX uptake and cytotoxicity. Similar to our study, Komoto et al. assessed the effects of 12 Ca2+ antagonists, including DIL, on MDR1 mRNA expression in human cervical carcinoma (HeLa and Hvr100-6 cells) previously treated with chemotherapeutic agents to find a novel strategy to reverse MDR1-mediated MDR [18]. Consistent with our findings, they found a significant reduction in MDR1 mRNA expression after DIL treatment but variable results for other Ca2+ antagonists, confirming that the down-regulation of MDR1 mRNA expression contributed to the reduction in resistance via increases in the intracellular concentrations of anticancer drugs. Moreover, Didziapetris et al. and Genovese et al. reported that DIL is an ABCB1 substrate that may inhibit ABCB1 expression [19, 20].

In addition, our result showed a 1.5 fold increase in FOXO3a expression, a tumor suppressor gene, after addition of DIL to DOX treatment (Fig. 3). This expression may be considered responsible for the increase in the cytotoxic activity of DOX. It is consistent with that of Farhan et al. who proposed that FOXO3a activation promotes cell cycle arrest and cancer cell apoptosis, which is beneficial for treating cancer [21]. It has been suggested that drugs that activate FOXO3a can be used in combination with other therapeutic agents to sensitize tumor cells [21, 22]. In the same manner, our present study also showed that the expression of the tumor suppressor gene p53 was increased after DOX treatment; this expression further increased by 1.5 fold after the addition of DIL (Table 1). Many studies have shown that the p53 signaling pathway is essential for DOX-induced cytotoxicity in cancer cells as DOX exerts its anticancer function by inducing cell cycle arrest and apoptosis in cancer cells [23, 24]. Dziegielew ska et al. reported that epithelial tumor cells express T-type Ca2+ channels, which are thought to promote cell proliferation and has more response to T-type Ca2+ channel inhibition. Selective T-type Ca2+ channel antagonists caused growth inhibition and apoptosis more effectively in the colon cancer cell (HCT116 cells) that expressed wild-type p53 [25].

The second part of this study aimed to study the protective effect of DIL against DOX cardiotoxicity in Wistar rats. As mentioned that the cardiotoxicity either acute or chronic is the major limiting complication of DOX treatment [5]. The mechanisms underlying the development of DOX-induced cardiotoxicity has poorly understood, although activation of several cellular pathways has been proposed, including the local release of vaso-active substances, mitochondrial dysfunction, lipid peroxidation and glutathione peroxidase depletion [26, 27]. In addition, much recent attention has been focused on the potential involvement of myocardial ROS, which is increased by DOX and modulate several of the key remodeling processes [28].

In the present study, the DOX-induced acute cardiotoxicity was indicated by the changes in the serum levels of total CK-MB (Table 2). It is well known that this enzyme is released from the heart muscle cells when they are injured and that its levels in the blood after myocardial injury reflect the extent of damage to the cardiac musculature. In addition, the MDA levels and TAC were variable and different from the normal levels. These results are in a good agreement with those of previous studies on DOX-induced cardiotoxicity that the oxidative stress was evident by the reduction in serum TAC (Table 4) and GPx levels (Table 5) and the increase in lipid peroxidation indicated by increased serum MDA levels (Table 3).

Due to its cardiotoxicity, various strategies have been employed to prevent this series of an adverse effect such as the use of combination treatment, cardioprotective
and synthesis of modified anthracyclines [29]. In this study, the addition of DIL to DOX treatment resulted in a twofold increase in the GPx levels and TAC and a twofold decrease in the MDA levels. These results are in good agreement with others who reported cardiac toxicity after DOX [30, 31]. They have shown a decreased serum level of TCA and increased the level of MDA after DOX administration in rats. Our data are also in a consistent with Feridooni et al. who found potential prevention or attenuation of anti-cancer drug-induced cardiotoxicity (Irinotecan and DOX) by using anti-ischemic drugs (losartan and DIL) plus dextrazoxane in (H9c2) rat cardiomyoblast cell line. They found that losartan and DIL were as effective as dextrazoxane in protecting the cardiac cells against irinotecan- and DOX-induced toxicity [32].

Our histopathological study confirmed our biochemical results by showing that DOX treatment disrupted normal cardiac architecture and caused fragmented cardiac muscle fibers in multiple areas. However, after the addition of DIL to DOX treatment, light microscopy showed normally branched cardiac muscle fibers with central vesicular nuclei and normal cardiomyocytes (Fig. 4a–d).

Overall, we have shown that DIL treatment increased cytotoxic effects of DOX against the growth of MCF-7 cells when given simultaneously, by induction of cell cycle arrest, promoting cell apoptosis, induction expression of tumor suppressor genes as FOXO3a and p53 as well as reverse resistance gene expression. In the other side, the cardiotoxicity induced by DOX was attenuated in the presence of DIL.

Conclusions
Our results suggest that addition of DIL may consider as a possible approach to enhance the cytotoxic activity of DOX against the growth of breast cancer cells by sensitizing its action, delay tumor growth through increased the activity of the tumor suppressor genes FOXO3a and p53 as well as ability to overcome the cell resistance through inhibition of P-gp expression. In addition, we also found that DIL treatment prevented DOX-induced cardiotoxicity in waster rat through its antioxidant properties that showed an increase in the level of GPx and TAC as well as a decreased in the level of MDA.

Acknowledgements
The present study funded by a grant from King Abdulaziz City for Science and Technology, Saudi Arabia (Ref. No. 1‑18‑13‑009‑0009). The authors, therefore, acknowledge and thank the KACST and for financial support. Only the authors listed on the manuscript contributed towards the article.

Authors’ contributions
Experimental work, HSAM, AMMO, AAAQ; cytopathological investigation, WSR; and others read and shared their interpretation of data and contributed in the writing of the manuscript. All authors read and approved the final manuscript.

Funding
This research has been funded by King Abdulaziz City for Science and Technology, Saudi Arabia, Grant Number 1‑18‑13‑009‑0009.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All animal studies were approved by the ethical research committee’s unit at the College of Medicine, King Abdulaziz University (Reference No. 190‑18).

Consent for publication
Consent has been taken from the institution and the patients. All the authors have approved the publication of this manuscript.

Competing interests
The authors declare they have no competing interests.

Author details
1 Pharmacology Department, Faculty of Medicine, KAU, Jeddah, Saudi Arabia.
2 Pharmacology Unit, National Cancer Institute, Cairo University, Cairo, Egypt.
3 Department of Genetic Medicine, Faculty of Medicine, KAU, Jeddah, Saudi Arabia.
4 Princess Aljawahra Center of Excellence in Research of Hereditary Disorders, KAU, Jeddah, Saudi Arabia.
5 Anatomy Department, Faculty of Medicine, KAU, Jeddah, Saudi Arabia.
6 Anatomy Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Received: 13 December 2018 Accepted: 16 July 2019
Published online: 24 July 2019

References
1. Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract. 1996;192:768–80.
2. Voulgaris G, Pintzas AS. Epithelial–mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009;1796:75–90.
3. Lopez V, Vici P, Fattoruso S. Making the right choice in the adjuvant chemotherapy of primary breast cancer. Eur J Cancer Suppl. 2008;6:10–2.
4. Briski R, Feldman AL, Bailey NG, Lim MS, Ristow K, Habermann TM, Macon WR, Inwards DJ, Colgan JP, Nowakowski GS, Kaminiski MS. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J. 2014;4:6214.
5. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302–14.
6. Smith L, Watson MB, O’Kane SL, Drev PJ, Lind MJ, Cawkwell L. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther. 2006;5:2115–20.
7. Moiseenko F, Volkov N, Bogdanov A, Dubina M, Moiseyenko V. Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion. F1000 Res. 2017;6:288–96.
8. Cornwell MM, Pastan I, Gottesman MM. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem. 1987;262:2166–70.
9. Šulić S, Panić L, Đikić I, Volarević S. Deregulation of cell growth and malignant transformation. Croat Med J. 2005;46:622–38.
10. McGroghan BT, Gilmarin B, Carney D, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785:96–132.
11. Zhou BBS, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408:433.
12. Ormrod D, Holm K, Gea K, Spencer C. Epirubicin. Drugs Aging. 1999;15:389–416.
13. Azz MFA, Abu N, Yeap SK, Ho WY, Omar AR, Ismail NH, Ahmad S, Pirzayan MR, Akhtar NM, Alitheen NB. Combinatorial cytotoxic effects of dacarbazine and doxorubicin against human breast cancer MCF-7 cells in vitro. Molecules. 2016;21:1228.
14. Schmidt WF, Huber KR, Ettinger RS, Neuberg RW. Antiproliferative effect of verapamil alone on brain tumor cells in vitro. Cancer Res. 1988;48:3617–21.
15. Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res. 1992;52:2413–8.
16. Martin HL, Smith L, Tomlinson DC. Multidrug-resistant breast cancer: current perspectives. Breast Cancer. 2014;6:1–13.
17. Vrana D, Hlavac V, Brynychova V, Vaclavikova R, Neoral C, Vrljic J, Aujesky R, Matzenauer M, Melichar B, Soucek P. ABC transporter and their role in the neoadjuvant treatment of esophageal cancer. Int J Mol Sci. 2018;19:868.
18. Komoto C, Nakamura T, Yamamori M, Ohmoto N, Kobayashi H, Kuwahara A, Nishiguchi K, Takara K, Tanigawara Y, Okamura N, Okumura K. Reversal effects of Ca2+ antagonists on multidrug resistance via down-regulation of MDR1 mRNA. Kobe J Med Sci. 2007;53:355–63.
19. Didziapetris R, Japertas P, Avdeef A, Petrasauskas A. Classification analysis of P-glycoprotein substrate specificity. J Drug Target. 2003;11:391–406.
20. Genovesi I, Ilani A, Assaraf YG, Fazi F, Colotti G. Not only P-glycoprotein Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist Updat. 2017;32:23–46.
21. Farhan M, Wang H, Gaur U, Little PJ, Xu J, Zheng W. FOXO Signaling pathways as therapeutic targets in cancer. Int J Bio Sci. 2017;13:815.
22. Taylor S, Lam M, Patarasa C, Brown JE, Carmichael AR, Griffiths HR. Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review. Cancer Cell Int. 2015;15:1.
23. Sun Y, Xia P, Zhang H, Liu B, Shi Y. P53 is required for Doxorubicin-induced apoptosis via the TGF-beta signaling pathway in osteosarcoma-derived cells. Am J Cancer Res. 2016;6:114.
24. Wang S, Konorev EA, Kotamraju S, Joseph J, Khalidani S, Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms intermediacy of H2O2 and p53-dependent pathways. J Biol Chem. 2004;279:25335–43.
25. Dziegielewski B, Brautigan DL, Larner JM, Dziegielewski J. T-type Ca2+ channel inhibition induces p53-dependent cell growth arrest and apoptosis through activation of p38 MAPK in colon cancer cells. Mol Cancer Res. 2014;12:348–58.
26. Volkova M, Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Cur Cardiol Rev. 2011;7:214–20.
27. Koka S, Kukreja RC. Attenuation of doxorubicin-induced cardiotoxicity by tadalafil: a long acting phosphodiesterase-5 inhibitor. Mol Cellular Pharmacol. 2010;2:173.
28. Jablonska-Trypald A, Kętrowski R, Kalinowska M, Świderski G, Cechowska-Pasko M, Lewandowski W. Possible mechanisms of the prevention of doxorubicin toxicity by cichoric acid—an antioxidant nutrient. Nutrients. 2018;10:44.
29. Alkraethy H, Damanhour ZA, Ahmed M, Ali SS, Osman AMM. Aged garlic extract protects against doxorubicin-induced cardiotoxicity in rats. Food Chem Toxicol. 2010;48:951–6.
30. Shaker RA, Abboud SH, Assaad HC, Hadi N. Enoxaparin attenuates doxorubicin-induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis. BMC Pharmacol Toxicol. 2018;19:3.
31. Kwatra M, Kumar V, Jangra A, Mishra M, Ahmed S, Ghosh P, Vohora D, Khanam R. Ameliorative effect of naringin against doxorubicin-induced acute cardiac toxicity in rats. Pharm Biol. 2016;54:637–47.
32. Feridooni T, Mac Donald C, Shao D, Yeung P, Agui RU. Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line. Acta Pharmacutica. 2013;63:493–503.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.